DESTINY Calls For Daiichi Sankyo/AZ’s Enhertu In Other Indications
Gastric, Lung And Colorectal Data Promising
Daiichi Sankyo and AstraZeneca’s ambitions to expand the use of their HER-2 targeted antibody-drug conjugate product beyond breast cancer are looking realizable on the back of new results presented at ASCO, but toxicities remain an issue.
